- Conditions
- Cardiovascular Disease, Spinal Cord Injury
- Interventions
- ERGYS BikeFunctional Electrical Stimulation Ergometry
- Device
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- The Bronx, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 884
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Transgenderism, Clotting Disorder
- Interventions
- Estradiol Tablets, Transdermal patch
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Gene Therapy, Hemophilia B
- Interventions
- Interview
- Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 14 more
- Conditions
- Hemophilia A
- Interventions
- Not listed
- Lead sponsor
- Victor J Marder, M.D.
- Other
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 24 more
- Conditions
- Blood Loss, Thrombosis, Extracorporeal Circulation; Complications
- Interventions
- Quantra System
- Diagnostic Test
- Lead sponsor
- HemoSonics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
- Conditions
- Essential Thrombocythemia
- Interventions
- Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Glendale, Arizona • Glendale, California • Stanford, California + 12 more
- Conditions
- Hemophilia A
- Interventions
- Emicizumab, FEIBA, rFVIIa
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Hemophilia A With Inhibitors
- Interventions
- recombinant activated factor VII
- Drug
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Other
- Eligibility
- Up to 8 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Atlanta, Georgia • Kansas City, Missouri
- Conditions
- Hemophilia A
- Interventions
- GreenGene™ F and an approved recombinant Factor VIII product, GreenGene™ F
- Biological
- Lead sponsor
- Green Cross Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Torrance, California + 7 more
- Conditions
- Blood Coagulation Disorders
- Interventions
- FFP Infusion
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 4 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 15
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 11 more
- Conditions
- Hemophilia A
- Interventions
- Nuwiq
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Immune Thrombocytopenia
- Interventions
- Rilzabrutinib
- Drug
- Lead sponsor
- Principia Biopharma, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 8
- States / cities
- Peoria, Illinois • Bethesda, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
- Interventions
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 7 Years to 11 Years · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Thrombocythemia, Essential, Primary Myelofibrosis
- Interventions
- Bomedemstat
- Drug
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Miami, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Interventions
- fostamatinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Factor XIII Deficiency
- Interventions
- FXIII Concentrate (Human)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Dothan, Alabama • Orange, California • San Francisco, California + 2 more
- Conditions
- Hemophilia B
- Interventions
- verbrinacogene setparvovec
- Genetic
- Lead sponsor
- Spur Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
- Conditions
- Immune Thrombocytopenia
- Interventions
- Eltrombopag, Romiplostim, healthy controls
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemophilia A
- Interventions
- Factor VIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 5 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Peoria, Illinois • Portland, Oregon
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri
- Conditions
- Hemophilia A, Prophylaxis of Bleeding
- Interventions
- Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more